EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). - Wikidata - awgldk - TriplyDB

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

http://www.wikidata.org/entity/Q35621625

about

A Practical Approach to Management of Chronic Hepatitis B Hepatitis B virus: inactive carriers Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection Liver Failure due to Acute Viral Hepatitis (A-E)Treatment of rheumatic diseases and hepatitis B virus coinfection Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement Quantitative measurement of serum hepatitis B surface antigen using an immunoradiometric assay in chronic hepatitis B Antiviral therapy and resistance with hepatitis B virus infection.Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.Prevalence of hepatitis D virus in hepatitis B virus infected patients referred to Taleghani hospital, Tehran, Iran Classification of Traditional Chinese Medicine Syndromes in Patients with Chronic Hepatitis B by SELDI-Based ProteinChip Analysis.Liver biopsy for histological assessment: The case against.Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis.New approaches in the management of chronic hepatitis B: role of tenofovir.Misperceptions among patients with chronic hepatitis B in Singapore.San Francisco hep B free: a grassroots community coalition to prevent hepatitis B and liver cancer.Emerging drugs for hepatitis B.Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase.Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV.Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies The safety of etanercept for the treatment of plaque psoriasis.Efficiency and safety of radiofrequency-assisted hepatectomy for hepatocellular carcinoma with cirrhosis: A single-center retrospective cohort study.Development and Application of the Chinese (Mainland) Version of Chronic Liver Disease Questionnaire to Assess the Health-Related Quality of Life (HRQoL) in Patients with Chronic Hepatitis B.Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.24 year outcomes of hepatitis B vaccination in Hangzhou, China.Estimation of Hepatitis B Virus, Hepatitis C Virus, and Different Clinical Parameters in the Thalassemic Population of Capital Twin Cities of Pakistan.Predicting survival in hepatitis B.The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity.Management of patients with HBeAg-negative chronic hepatitis B Immunoregulation of hepatitis B virus infection--rationale and clinical application Changes in seroprevalence of hepatitis B surface antigen and epidemiologic characteristics in the Republic of Korea, 1998-2013 Future prospectives for the management of chronic hepatitis B.

P2860

Q24810145-4A23FD3C-F0A0-4348-868C-E075E6EC8052 Q24810833-8230CA83-17B8-456B-A6AC-566A2603E934 Q24815355-A5632A7D-28A1-44E0-8412-DBEE5F8CCEF3 Q26740326-242BA5BB-13E1-487B-95E1-DE57CDC6A210 Q28084305-D696E0EA-FED7-4915-90AA-55E4AD8D33C2 Q30389962-D244F091-CF5E-4DCC-AEAE-E4F3EAEFE009 Q33704165-4F1E6214-7068-4B11-A72F-F085A00EDF16 Q33787531-504D44F9-9E76-4694-B12C-15620454EAD7 Q33866383-F2531FD7-A394-4556-A560-0E57D223D363 Q33879651-C4192D93-F65E-4623-8202-94F62DD504EC Q33926126-46D7F521-FC65-498B-86F8-DAFE7308889D Q34031396-43D84977-ADAE-40D7-98ED-90186385A8D2 Q34302199-398D4B30-8EC2-472A-8965-002FFCF5F37B Q34469006-9400D210-5FCB-42B3-B440-0E65AF1E9816 Q34569230-2FF536AC-831A-42EA-9A21-78CE71391BBF Q34657327-BBE932FF-7B97-4635-8C81-9EE00EEB418D Q35026531-43122FF3-21B4-4EBB-80A7-8051C29B900A Q35064498-62E0B24D-218E-47DF-84DD-4BA444BF4762 Q35089793-FBF8FCE6-E526-493F-9374-7F6F01A940A3 Q35359369-C29D2C6F-EF7D-4623-A37F-E5EEFD29FC17 Q35362817-19434B3F-6E43-4899-826C-131BBA31282B Q35433965-1A2F0DAA-B46C-4DB1-8FEC-CA29557CDC86 Q35507274-D2CC5ACD-B688-480B-91F6-49FFBFF5F793 Q35579382-6F13AE25-0283-4768-BC3E-065E3B650305 Q35615890-E72F484D-DC60-4F3E-ACB8-95A3E306DFEB Q35637506-ECF1D1AB-3728-4D25-99A1-DF619F9B1607 Q35919214-477A582C-4CB6-47F9-B88B-A59A95DF42EF Q36067582-4C7B6932-A30D-4A1E-99C8-E77E18130909 Q36134339-DC218797-F476-40F6-A4BC-046E58C55D8A Q36181175-76EABDAC-389C-4CFD-ABF2-3F71AAE9284A Q36256369-59F76C9C-2001-4328-B8E6-57CDD57D9FFB Q36257127-8807E205-70E7-42DC-B6A0-2CE7D1D82067 Q36287594-F66CA77E-FF8A-47CB-A667-8A7DB920738B Q36301502-FF98A495-C9F0-43DD-9452-9B04E2F86F75 Q36314573-849B49B7-24A3-472F-AECE-D34985A10EC1 Q36422622-0BCBD616-092A-473D-B5B8-0CDD4587AB9B Q36724421-8A75136B-E9C7-4568-8F1B-5516DDBE38B1 Q36797085-71F10DA0-C82B-4108-99C3-DF7D7DFDA106 Q36810037-39A513C4-C024-49BF-B7A5-DD84D47BFE18 Q36841719-2CDAB7DD-60A3-4D14-B9A6-EA5CCC3934A3

P2860

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

http://www.wikidata.org/entity/Q35621625

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

EASL International Consensus C ...... nsus statement (long version).

@ast

EASL International Consensus C ...... nsus statement (long version).

@en

type

label

EASL International Consensus C ...... nsus statement (long version).

@ast

EASL International Consensus C ...... nsus statement (long version).

@en

prefLabel

EASL International Consensus C ...... nsus statement (long version).

@ast

EASL International Consensus C ...... nsus statement (long version).

@en

P1433

Q35621625-342173E0-FF6A-4B61-875E-9FBC0355FD50

P1476

Q35621625-1F419C7B-088A-409C-988C-7A638E57ABBC

P2093

Q35621625-0FA1F700-96FB-465A-934E-32D754654F00

Q35621625-26488E87-BC67-43B1-9FFB-DB6C2AE80ABE

Q35621625-5254A5B1-68A6-4824-A805-8A07627ADA25

Q35621625-65821104-12A4-4C52-B411-1A44C4E9A243

Q35621625-6C32B83F-0638-4CBF-9C1A-7716032F4459

Q35621625-7256FB18-B24E-49BD-8593-237D8384439F

Q35621625-7D5B5B1C-BF66-499C-9062-96D4B129D16A

Q35621625-96AF373B-6198-4AB2-8567-1744828F513E

Q35621625-D87067D1-1329-4BEF-A828-01D65EA96ACF

Q35621625-ECB7DE95-B7DF-4AE3-9ADA-F866ACC2EBE4

P304

Q35621625-2677C285-83BB-447B-9F97-9ABB3C1672BF

P31

Q35621625-F58241C3-AF61-45E3-ABD0-A70ADE55526C

Q35621625-b5b03535-8ed7-4022-9b72-33ecaded0cd6

P478

Q35621625-C7E0C3FB-0561-40B1-8059-517E0DF0177F

P577

Q35621625-53C44A22-4876-4602-9DEB-FF9E4717EE9F

P698

Q35621625-F162574A-6FF1-43C7-B2EB-1D66E88A61A7

P1433

Journal of Hepatology

P1476

EASL International Consensus C ...... nsus statement (long version).

@en

P2093

Alfonso Mele

http://www.w3.org/2001/XMLSchema#string

Anna Lok

http://www.w3.org/2001/XMLSchema#string

Antoine Hadengue

http://www.w3.org/2001/XMLSchema#string

Antonello Pietrangelo

http://www.w3.org/2001/XMLSchema#string

Daniel Lavanchy

http://www.w3.org/2001/XMLSchema#string

Dominique Valla

http://www.w3.org/2001/XMLSchema#string

EASL Jury

http://www.w3.org/2001/XMLSchema#string

George Lau

http://www.w3.org/2001/XMLSchema#string

Gustav Paumgartner

http://www.w3.org/2001/XMLSchema#string

Juan Rodés

http://www.w3.org/2001/XMLSchema#string

P304

S3-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

39 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14708673

http://www.w3.org/2001/XMLSchema#string